KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Royalty Pharma (RPRX) Equity Income (2019 - 2025)

Royalty Pharma (RPRX) has disclosed Equity Income for 7 consecutive years, with $86.7 million as the latest value for Q4 2025.

  • Quarterly Equity Income rose 173.8% to $86.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $111.7 million through Dec 2025, down 1.21% year-over-year, with the annual reading at $29.1 million for FY2025, 1.76% down from the prior year.
  • Equity Income hit $86.7 million in Q4 2025 for Royalty Pharma, up from $15.9 million in the prior quarter.
  • In the past five years, Equity Income ranged from a high of $86.7 million in Q4 2025 to a low of -$47.1 million in Q2 2024.
  • Historically, Equity Income has averaged $17.5 million across 5 years, with a median of $4.6 million in 2025.
  • Biggest five-year swings in Equity Income: plummeted 1974.5% in 2022 and later surged 8616.88% in 2023.
  • Year by year, Equity Income stood at -$1.5 million in 2021, then tumbled by 1974.5% to -$31.3 million in 2022, then skyrocketed by 276.04% to $55.1 million in 2023, then plummeted by 42.61% to $31.6 million in 2024, then soared by 173.8% to $86.7 million in 2025.
  • Business Quant data shows Equity Income for RPRX at $86.7 million in Q4 2025, $15.9 million in Q3 2025, and $2.7 million in Q2 2025.